Allarity Therapeutics Inc (ALLR)

$0.64

+0.06

(+10.48%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Allarity Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.5% return, outperforming this stock by 153.6%

Performance

  • $0.55
    $0.65
    $0.64
    downward going graph

    14.02%

    Downside

    Day's Volatility :15.34%

    Upside

    1.54%

    downward going graph
  • $0.55
    $283.20
    $0.64
    downward going graph

    13.86%

    Downside

    52 Weeks Volatility :99.81%

    Upside

    99.77%

    downward going graph

Returns

PeriodAllarity Therapeutics IncIndex (Russel 2000)
3 Months
-92.69%
0.0%
6 Months
13.32%
0.0%
1 Year
-95.12%
0.0%
3 Years
-100.0%
-20.1%

Highlights

Market Capitalization
11.0M
Book Value
- $15.26
Earnings Per Share (EPS)
-205.2
Wall Street Target Price
5.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-81.08%
Return On Equity TTM
-20995.16%
Revenue TTM
-7.1M
Revenue Per Share TTM
-0.02
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-36.3M
EBITDA
-17.1M
Diluted Eps TTM
-205.2
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.6
EPS Estimate Next Year
-1.56
EPS Estimate Current Quarter
-1.76
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Sell
    0
    0%Buy
    50%Hold
    50%Sell
Based on 6 Wall street analysts offering stock ratings for Allarity Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
00
Hold
3
3
3
Sell
3
3
3

Analyst Forecast

What analysts predicted

Upside of 681.25%

Current $0.64
Target $5.00

Technicals Summary

Sell

Neutral

Buy

Allarity Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Allarity Therapeutics Inc
Allarity Therapeutics Inc
-59.2%
13.32%
-95.12%
-100.0%
-100.0%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Allarity Therapeutics Inc
Allarity Therapeutics Inc
0.0
NA
NA
-2.6
-209.95
-0.81
NA
-15.26
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Allarity Therapeutics Inc
Allarity Therapeutics Inc
Sell
$11.0M
-100.0%
0.0
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • TWO SIGMA SECURITIES, LLC

    0.64%

  • Citadel Advisors Llc

    0.45%

  • Virtu Financial LLC

    0.25%

  • Tower Research Capital LLC

    0.09%

Company Information

oncology venture is a drug development company formed in 2012 dedicated to unlock the potential of new oncology products, and rescue failed drugs. our method improves the efficacy of the drugs, increase the response rate in cancer patients, reduce timelines and improve success rates in oncology drug development.

Organization
Allarity Therapeutics Inc
Employees
5
CEO
Mr. Thomas H. Jensen
Industry
Miscellaneous

Discover More

FAQs